HOME | COUNTRIES | CITIES | COMPANIES | SPORTS | CARS
news videos images websites
 


Merck Co Company News

Thu, 03 Nov 2016 07:04:10 GMT
Investment Analysts' Weekly Ratings Updates for Merck & Co. (MRK)  -  DailyQuint
Merck & Co. (NYSE: MRK) has recently received a number of price target changes and ratings updates: Merck & Co. (NYSE:MRK) opened at 59.30 on Wednesday. The firm has a market cap of $163.98 billion, a price-to-earnings ratio of 30.29 and a beta of ...
Thu, 03 Nov 2016 06:23:03 GMT

Merck drug shows promise in Alzheimer's disease  -  PharmaTimes
Merck & Co's BACE1 inhibitor verubecestat has shown promise in a Phase I trial assessing its potential in Alzheimer's disease. The randomised, double-blind, placebo-controlled multiple dose study assessed the safety and tolerability, pharmacokinetics ...
Thu, 03 Nov 2016 04:56:25 GMT
Are You Familiar with Analyst's Earnings Estimates? Merck & Company, Inc. (NYSE:MRK) , Tandem Diabetes Care, Inc ...  -  Is stories
On 11/2/2016, Merck & Company, Inc. (NYSE:MRK) dropped -0.78% and ended at $58.84. The stock's market capitalization arrived at $162.70B and total traded volume was 10.72 million shares. The stock has a 52-week highest price of $64.86 and its ...
Thu, 03 Nov 2016 03:24:06 GMT
Verastem licenses exclusive rights to develop & commercialize Infinity Pharma's oncology product, duvelisib  -  pharmabiz.com
These studies are combination clinical trials with pembrolizumab or avelumab from Merck & Co. and Pfizer/Merck KGaA, respectively. Verastem also owns rights to the FAK inhibitor VS-4718 and the dual PI3K and mTORC1/2 inhibitor VS-5584 which are both ...
Wed, 02 Nov 2016 23:12:23 GMT
Is this Large Market Cap Stock target price reasonable for Merck & Co., Inc. (NYSE:MRK)?  -  The Daily Leicester
The company in question is, Merck & Co., Inc. (NYSE:MRK) currently with a stock price of 59.3 (0.99% today). The market cap for Merck & Co., Inc. is 166886.21, and is in the sector Healthcare, and Drug Manufacturers – Major industry. The target price ...
Wed, 02 Nov 2016 22:11:46 GMT
Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 ...  -  PharmiWeb.com (press release)
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are ...
Wed, 02 Nov 2016 22:00:05 GMT
Merck & Company Inc. (new) (MRK) Closes 0.78% Down on the Day for November 02  -  Equities.com
Dow Jones component Merck & Company Inc. (new) (MRK) saw its stock move -0.78% to $58.84, representing a per-share move of $0.46, on volume of 10.68 million shares for Wednesday. Merck & Company Inc. (new) currently has a total float of 2.77 billion ...
Wed, 02 Nov 2016 16:51:15 GMT

Merck partners “Women for Cancer” to empower women cancer survivors in Africa  -  Naija247news
Merck , a leading science and technology company, today announced the kick off of “Merck More than a Patient” which is a new initiative of “Merck Cancer Access Program” in Africa. Merck in partnership with “Women for Cancer” started this initiative ...
Wed, 02 Nov 2016 15:24:42 GMT

These Are Analyst Ratings Worth Watching: Merck & Co., Inc. (NYSE:MRK), Macy's, Inc. (NYSE:M)  -  Review Fortune
Merck & Co., Inc. (NYSE:MRK) made a 0.99% move from the market's previous close, putting the price on the $59.30 per share as of 11/01/2016. The total volume of shares traded was above their three months average volume of 10,730,000 shares. The firm ...
Wed, 02 Nov 2016 14:56:21 GMT
Analyst Stock Ratings: Merck & Co., Inc. (NYSE:MRK), Neovasc Inc. (NASDAQ:NVCN)  -  TWN
At the most recent close, Merck & Co., Inc. (NYSE:MRK) tinted gains of +0.99% (+0.58 points) to US$59.3. The volume of 14.31 Million shares climbed up over an trading activity of 10.73 Million shares. EPS ratio determined by looking at last 12 month ...